| | By Nick Paul Taylor Novartis is coming for the jewels of AstraZeneca’s $39 billion takeover of Alexion. In a phase 3 trial, the Swiss drugmaker’s iptacopan beat the incumbent rare disease drugs Soliris and Ultomiris, advancing its plan to turn the oral challenger into a $3 billion-a-year blockbuster. |
|
|
|
By Zoey Becker In a case that kicked off in 2018, the husband and wife duo of Allen and Xanthe Lam were sentenced to six months of imprisonment each for stealing Genentech trade secrets and handing them off to JHL Biotech. The two were also dealt fines of more than $10,000. |
By Gabrielle Masson After a second patient death, Alpine Immune Sciences is terminating enrollment for two trials assessing its cancer asset davoceticept, including the biotech’s combo study with Merck’s Keytruda for adults with advanced malignancies. |
By Fraiser Kansteiner On the quest to simplify its operations in a post-Haleon world, GSK is “bringing together our medicines and vaccines manufacturing networks, and equivalent commercial operations, in one place,” a company spokesperson said. At the same time, 25-year veteran Roger Connor is departing his post as GSK’s president of vaccines and global health. |
|
Tuesday, November 1, 2022 | 11am ET / 8am PT In this insightful webinar, you’ll hear how life science brand leaders can leverage EHR systems to dramatically increase successful enrollment for patient support programs. Register now.
|
|
By Nick Paul Taylor AstraZeneca has pulled off a pair of wins in breast cancer. After seeing rival drugs from Roche and Sanofi fail, the Anglo-Swedish drugmaker bucked the trend with wins for capivasertib and camizestrant in phase 2 and 3 clinical trials. |
By Kevin Dunleavy Pfizer revealed during an investor call that it is considering charging between $110 and $130 per dose for its COVID shot Comirnaty, which was co-developed by BioNTech. The new price will take effect sometime in 2023—likely in the first quarter—when the U.S. exhausts its stockpile of COVID vaccines and transitions to a commercial model. |
By Andrea Park Barely one week into his tenure as president and CEO of Philips, Roy Jakobs is already being put to the test. |
By Angus Liu AstraZeneca’s long-troubled cancer immunotherapy tremelimumab has finally secured its first FDA approval, but the regulatory blessing comes in what could be an increasingly competitive tumor type. |
By Helen Floersh Neurons in the part of the brain that controls the fear response may also be responsible for the tendency to overeat fatty, sugary foods. |
By Fraiser Kansteiner Following an October FDA inspection, Lupin’s biotech manufacturing facility in Pune, India, has been slapped with a 17-observation Form 483. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Wednesday, November 2, 2022 | 1pm ET / 10am PT This webinar will discuss how Invitae and others are working together to characterize the lived experience of patients with rare bile duct cancer, and ultimately, improve patient care. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| |
|
